COVID-19 infection is not associated with immediate changes in multiple sclerosis symptom severity or disability.

A recent study finds health care spending in the United States reached $4.9 trillion and increased 7.5 percent in 2023.

The FDA has granted Fast Track designation to LPCN 1148 for the treatment of sarcopenia in patients with decompensated cirrhosis.

A recent study finds that the prevalence of post-COVID-19 condition was 8.4 percent among U.S. adults in 2023.

Upadacitinib demonstrated long-term efficacy for the treatment of ankylosing spondylitis among patients who failed to respond to prior biologic therapy.

Higher FT4 levels were associated with increased risks for knee OA prevalence, severity, and progression, especially among patients with greater joint loading.

Black children are suspected to have experienced child abuse at higher rates than children of other racial and ethnic backgrounds.

Topline data were announced from a phase 3 trial evaluating CagriSema in overweight or obese patients without type 2 diabetes.

Despite advances, there remain gaps in the understanding of and personalized treatment for chronic pain in rheumatology, especially among women.

A brief outpatient rehabilitation program with a cognitive and behavioral approach is effective for patients with post-COVID-19 condition.

The FDA has approved Steqeyma® (ustekinumab-stba), a biosimilar to Stelara®, for the treatment of various chronic ...

HealthDay News — Substance use among adolescents has continued to hold steady at lowered levels for the fourth year in a row, according to the U.S. National Institutes of Health (NIH)-funded ...